Lu Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lu Zhou has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Bingqiang Ni
Department of Oncology The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning Nanning China
1 shared publication - Chunjiao Yang
Department of Oncology, The Fifth Affiliated Hospital of Guangxi Medical University and The First People’s Hospital of Nanning, Nanning 530021, China
1 shared publication - Huayun Wu
Department of Oncology The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning Nanning China
1 shared publication Jiao Liu
Shenzhen Longhua Maternity and Child Healthcare Hospital Shenzhen China
1 shared publication- Liansheng Tian
Benxi Central Hospital Benxi China
1 shared publication - Ling Liu
Benxi Central Hospital Benxi China
1 shared publication
Latest Publications
- 9 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (13) , e23802
Systematic pan‐cancer analysis insights into ICAM1 as an immunological and prognostic biomarker
Intercellular adhesion molecule 1 (ICAM1) is a cell surface adhesion glycoprotein in the immunoglobulin supergene family. It is associated with several epithelial tumorigenesis processes, as well as with inflammation. However, the function of ICAM1 in the prognosis of tumor immunity is still unclear. This study aimed to examine the immune function of ICAM1 in 33 tumor types and to investigate the prognostic value of tumors. Using datasets from the Cancer Genome Atlas (TCGA), Genotype Tissue Expression (GTEx), Cancer Cell Lines Encyclopedia (CCLE), Human Protein Atlas (HPA), and cBioPortal, we investigated the role of ICAM1 in tumors. We explored the potential correlation between ICAM1 expression and tumor prognosis, gene mutations, microsatellite instability, and tumor immune cell levels in various cancers. We observed that ICAM1 is highly expressed in multiple malignant tumors. Furthermore, ICAM1 is negatively or positively associated with different malignant tumor prognoses. The expression levels of ICAM1 were correlated with the tumor mutation burden (TMB) in 11 tumors and with MSI in eight tumors. ICAM1 is a gene associated with immune infiltrating cells, such as M1 macrophages and CD8+ T cells in gastric and colon cancer. Meanwhile, the expression of ICAM1 is associated with several immune‐related functions and immune‐regulation‐related signaling pathways, such as the chemokine signaling pathway. Our study shows that ICAM1 can be used as a prognostic biomarker in many cancer types because of its function in tumorigenesis and malignant tumor immunity.
- 9 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (13) , e23802
Systematic pan‐cancer analysis insights into ICAM1 as an immunological and prognostic biomarker
Intercellular adhesion molecule 1 (ICAM1) is a cell surface adhesion glycoprotein in the immunoglobulin supergene family. It is associated with several epithelial tumorigenesis processes, as well as with inflammation. However, the function of ICAM1 in the prognosis of tumor immunity is still unclear. This study aimed to examine the immune function of ICAM1 in 33 tumor types and to investigate the prognostic value of tumors. Using datasets from the Cancer Genome Atlas (TCGA), Genotype Tissue Expression (GTEx), Cancer Cell Lines Encyclopedia (CCLE), Human Protein Atlas (HPA), and cBioPortal, we investigated the role of ICAM1 in tumors. We explored the potential correlation between ICAM1 expression and tumor prognosis, gene mutations, microsatellite instability, and tumor immune cell levels in various cancers. We observed that ICAM1 is highly expressed in multiple malignant tumors. Furthermore, ICAM1 is negatively or positively associated with different malignant tumor prognoses. The expression levels of ICAM1 were correlated with the tumor mutation burden (TMB) in 11 tumors and with MSI in eight tumors. ICAM1 is a gene associated with immune infiltrating cells, such as M1 macrophages and CD8+ T cells in gastric and colon cancer. Meanwhile, the expression of ICAM1 is associated with several immune‐related functions and immune‐regulation‐related signaling pathways, such as the chemokine signaling pathway. Our study shows that ICAM1 can be used as a prognostic biomarker in many cancer types because of its function in tumorigenesis and malignant tumor immunity.